Iptacopan offers a unique advantage over current SoC anti-C5 antibody therapies (eculizumab or ravulizumab), which are associated with a high risk of infection by encapsulated bacteria, because it does not fully block the generation of MAC initiated by the classical and lectin complement pathways, and thus infection risk should theoretically be reduced. This evidence concerns the gene UBXN11 and infection.